Nestlé Subsidiary Acquires U.K. Medical Food Company

Nestlé Health Science has completed the acquisition of CM&D Pharma Ltd. (CM&D), a British company that develops medical foods and other products targeting patients with kidney disease, inflammatory bowel disease, and colon cancer. CM&D is a portfolio company of venture capital fund Inventages Group. CM&D’s leading product, Fostrap, is a chewing gum for kidney patients with elevated levels of phosphate in the blood (hyperphosphatemia), which contributes to vascular calcification and an increased risk of cardiac mortality, as well as mineral and bone disorders. Clinical trials of Fostrap are ongoing, though preliminary data are promising, according to Nestlé.